ANIXA BIOSCIENCES, INC. Impairment of Intangible Assets (Excluding Goodwill)
ANIXA BIOSCIENCES, INC. (ANIX) reported Impairment of Intangible Assets (Excluding Goodwill) of $418.75 thousand for the 12-month period ending 2019-10-31, per its 10-K filed 2021-01-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2021-01-07
- ANIXA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-10-31 was $0.00.
- ANIXA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-07-31 was $0.00.
- ANIXA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-04-30 was $0.00.
- ANIXA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-01-31 was $418.75K.
- ANIXA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for fiscal 2019 was $418.75K, a 28.17% decline from fiscal 2018.
- ANIXA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for fiscal 2018 was $582.98K.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|---|
| 2019-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-01-07 | $0.00 derived: sum of 2 quarters · filed 2021-01-07 | $0.00 derived: sum of 3 quarters · filed 2021-01-07 | $418.75K 10-K · filed 2021-01-07 | |
| 2019-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-09-08 | $0.00 derived: sum of 2 quarters · filed 2020-09-08 | $418.75K 10-Q · filed 2020-09-08 | ||
| 2019-04-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-06-09 | $418.75K 10-Q · filed 2020-06-09 | |||
| 2019-01-31 | $419.00K 10-K · filed 2020-01-09 | $418.75K 10-Q · filed 2020-03-09 | |||
| 2018-10-31 | $583.00K 10-K · filed 2020-01-09 | $582.98K 10-K · filed 2020-01-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |